Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints
Although inotersen met efficacy endpoints in Phase III familial amyloidosis study, adverse event rates raised a red flag and give Alnylam's competing patisiran an edge on safety, at least for now.
You may also be interested in...
Although tafamidis has been stalled at FDA for transthyretin-mediated polyneuropathy, Pfizer may have found a different path toward US approval with cardiovascular outcomes data in cardiomyopathy.
The latest drug development news and highlights from our US FDA Performance Tracker.
The latest drug approval and development news from our US FDA Performance Tracker.